Patents by Inventor Lynn MacDonald

Lynn MacDonald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NON-HUMAN ANIMALS COMPRISING A HUMANIZED COAGULATION FACTOR 12 LOCUS
    Publication number: 20200315149
    Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized coagulation factor XII (F12) locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized F12 locus express a human coagulation factor XII protein or a chimeric coagulation factor XII protein, fragments of which are from human coagulation factor XII. Methods are provided for using such non-human animals comprising a humanized F12 locus to assess in vivo efficacy of human-coagulation-factor-XII-targeting reagents such as nuclease agents designed to target human F12. A short isoform of F12 that is produced locally in the brain, and methods of using the short isoform, are also provide.
    Type: Application
    Filed: April 2, 2020
    Publication date: October 8, 2020
    Inventors: Yajun Tang, Dan Chalothorn, Lyndon Mitnaul, Lori Morton, Daria Zamolodchikov, Nicole Alessandri-Haber, Lynn Macdonald
  • Vantigen binding proteins exhibiting distinct binding characteristics
    Patent number: 10787522
    Abstract: Methods for making, identifying, isolating and/or making binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Exemplary binding proteins specific to small molecules are also provided.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: September 29, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Robert Babb, Ashique Rafique, Tammy T. Huang, Ergang Shi, Lynn Macdonald, Andrew J. Murphy
  • Multivalent Antigen-Binding Proteins
    Publication number: 20200299414
    Abstract: Multivalent antigen-binding proteins comprising two or three or four or more immunoglobulin heavy chain variable domain binding domains are provided, as are methods for making them, nucleic acid constructs, and cell lines for making them. Protein comprising two or three or four or more different heavy chain variable domains that lack an immunoglobulin variable domain are provided. Proteins comprising two or three or four or more different heavy chain variable domains that associate with the same immunoglobulin light chain variable domain are also provided.
    Type: Application
    Filed: March 4, 2020
    Publication date: September 24, 2020
    Inventors: George D. Yancopoulos, Nicholas J. Papadopoulos, Neil Stahl, Samuel Davis, Andrew J. Murphy, Lynn Macdonald
  • Genetically modified major histocompatibility complex animals
    Patent number: 10779520
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: September 22, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, Cagan Gurer, John McWhirter, Vera Voronina, Faith Harris, Sean Stevens, Yingzi Xue
  • NON-HUMAN ANIMALS HAVING HUMANIZED FC-GAMMA RECEPTORS
    Publication number: 20200288684
    Abstract: Genetically modified mice and methods and compositions for making and using the same are provided, wherein the genetic modification comprises humanization of an Fc?RI protein.
    Type: Application
    Filed: December 20, 2019
    Publication date: September 17, 2020
    Inventors: Andrew J. Murphy, Lynn Macdonald, Cagan Gurer, Karolina A. Meagher, Naxin Tu
  • HUMANIZED NON-HUMAN ANIMALS WITH RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN LOCI
    Publication number: 20200281175
    Abstract: Mice, embryos, cells, and tissues having a restricted immunoglobulin heavy chain locus and an ectopic sequence encoding one or more ADAM6 proteins are provided. In various embodiments, mice are described that have humanized endogenous immunoglobulin heavy chain loci and are capable of expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof that is functional in a male mouse. Mice, embryos, cells, and tissues having an immunoglobulin heavy chain locus characterized by a single human VH gene segment, a plurality of human DH gene segments and a plurality of human JH gene segments and capable expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof are also provided.
    Type: Application
    Filed: April 15, 2020
    Publication date: September 10, 2020
    Inventors: Lynn Macdonald, Sean Stevens, Andrew J. Murphy, Margaret Karow, John McWhirter
  • Restricted Immunoglobulin Heavy Chain Mice
    Publication number: 20200277371
    Abstract: Mice having a restricted immunoglobulin heavy chain locus are provided, wherein the locus is characterized by a single polymorphic human VH gene segment, a plurality of human DH gene segments and a plurality of JH gene segments. Methods for making antibody sequences that bind an antigen (e.g., a viral antigen) are provided, comprising immunizing a mouse with an antigen of interest, wherein the mouse comprises a single human VH gene segment, a plurality of human DH gene segments and a plurality of JH gene segments, at the endogenous immunoglobulin heavy chain locus.
    Type: Application
    Filed: April 17, 2020
    Publication date: September 3, 2020
    Inventors: Lynn Macdonald, John McWhirter, Andrew J. Murphy
  • RODENTS HAVING GENETICALLY MODIFIED SODIUM CHANNELS AND METHODS OF USE THEREOF
    Publication number: 20200267950
    Abstract: Disclosed herein are rodents (such as mice and rats) genetically modified at an endogenous Scn9a locus to comprise an exogenous Scn nucleotide sequence such as the coding sequence of a human SCN2A gene. Also disclosed are methods and compositions useful for making such rodents, and methods of using such rodents for generating anti-NaV1.7 antibodies.
    Type: Application
    Filed: February 21, 2020
    Publication date: August 27, 2020
    Inventors: Nicole Alessandri-Haber, Andrew J. Murphy, Lynn Macdonald
  • Method of treating osteoarthritis with an antibody to NGF
    Patent number: 10745471
    Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: August 18, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
  • HUMAN LAMBDA LIGHT CHAIN MICE
    Publication number: 20200239837
    Abstract: Genetically modified mice are provided that express human ? variable (hV?) sequences, including mice that express hV? sequences from an endogenous mouse ? light chain locus, mice that express hV? sequences from an endogenous mouse ? light chain locus, and mice that express hV? sequences from a transgene or an episome wherein the hV? sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human ? variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human ? variable sequences, including human antibodies, are provided.
    Type: Application
    Filed: February 12, 2020
    Publication date: July 30, 2020
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Andrew J. Murphy, Karolina A. Meagher
  • HUMANIZED LIGHT CHAIN MICE
    Publication number: 20200221675
    Abstract: Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin ? light chain variable domain.
    Type: Application
    Filed: December 30, 2019
    Publication date: July 16, 2020
    Inventors: Lynn Macdonald, Cagan Gurer, Karolina A. Hosiawa, Sean Stevens, Andrew J. Murphy
  • HUMANIZED LIGHT CHAIN MICE
    Publication number: 20200221676
    Abstract: Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin ? light chain variable domain.
    Type: Application
    Filed: December 30, 2019
    Publication date: July 16, 2020
    Inventors: Lynn Macdonald, Cagan Gurer, Karolina A. Hosiawa, Sean Stevens, Andrew J. Murphy
  • NUCLEASE-MEDIATED DNA ASSEMBLY
    Publication number: 20200208161
    Abstract: Methods are provided herein for assembling at least two nucleic acids using a sequence specific nuclease agent (e.g., a gRNA-Cas complex) to create end sequences having complementarity and subsequently assembling the overlapping complementary sequences. The nuclease agent (e.g., a gRNA-Cas complex) can create double strand breaks in dsDNA in order to create overlapping end sequences or can create nicks on each strand to produce complementary overhanging end sequences. Assembly using the method described herein can assemble any nucleic acids having overlapping sequences or can use a joiner oligo to assemble sequences without complementary ends.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Chris Schoenherr, John McWhirter, Corey Momont, Caitlin L. Goshert, Lynn Macdonald, Gregg S. Warshaw, Jose F. Rojas, Ka-Man Venus Lai, David M. Valenzuela, Andrew J. Murphy
  • ADAM6 mice
    Patent number: 10694725
    Abstract: Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: June 30, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Andrew J. Murphy, Margaret Karow
  • Mice that produce hybrid antibodies
    Patent number: 10640800
    Abstract: Provided herein is a mouse that produces hybrid antibodies containing human variable regions and mouse constant regions.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: May 5, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, George D. Yancopoulos, Margaret Karow, Lynn MacDonald, Sean Stevens, Aris N. Economides, David M. Valenzuela
  • B cell lineage based immunogen design with humanized animals
    Patent number: 10626168
    Abstract: Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in B-cell-lineage immunogen design in vaccine development are provided, as are methods of carrying out such design.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: April 21, 2020
    Assignees: REGENERON PHARMACEUTICALS, INC., DUKE UNIVERSITY
    Inventors: Barton Haynes, Garnett Kelsoe, Israel Lowy, Aris I. Baras, Lynn MacDonald, John McWhirter, Cagan Gurer, Karolina A. Meagher, Andrew J. Murphy, George D. Yancopoulos
  • Nuclease-mediated DNA assembly
    Patent number: 10626402
    Abstract: Methods are provided herein for assembling at least two nucleic acids using a sequence specific nuclease agent (e.g., a gRNA-Cas complex) to create end sequences having complementarity and subsequently assembling the overlapping complementary sequences. The nuclease agent (e.g., a gRNA-Cas complex) can create double strand breaks in dsDNA in order to create overlapping end sequences or can create nicks on each strand to produce complementary overhanging end sequences. Assembly using the method described herein can assemble any nucleic acids having overlapping sequences or can use a joiner oligo to assemble sequences without complementary ends.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: April 21, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Chris Schoenherr, John McWhirter, Corey Momont, Caitlin L. Goshert, Lynn MacDonald, Gregg S. Warshaw, Jose F. Rojas, Ka-Man Venus Lai, David M. Valenzuela, Andrew J. Murphy
  • HUMANIZED NON-HUMAN ANIMALS WITH RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN LOCI
    Publication number: 20200093106
    Abstract: Mice, embryos, cells, and tissues having a restricted immunoglobulin heavy chain locus and an ectopic sequence encoding one or more ADAM6 proteins are provided. In various embodiments, mice are described that have humanized endogenous immunoglobulin heavy chain loci and are capable of expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof that is functional in a male mouse. Mice, embryos, cells, and tissues having an immunoglobulin heavy chain locus characterized by a single human VH gene segment, a plurality of human DH gene segments and a plurality of human JH gene segments and capable expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof are also provided.
    Type: Application
    Filed: December 4, 2019
    Publication date: March 26, 2020
    Inventors: Lynn Macdonald, Sean Stevens, Andrew J. Murphy, Margaret Karow, John McWhirter
  • Mice that produce hybrid antibodies
    Patent number: 10584364
    Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: March 10, 2020
    Assignee: Rgeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, George D. Yancopoulos, Margaret Karow, Lynn Macdonald, Sean Stevens, Aris N. Economides, David M. Valenzuela
  • ADAM6 mice
    Patent number: 10577430
    Abstract: Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: March 3, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Andrew J. Murphy, Margaret Karow